Revenue grew 44% to $4.9 million, driven by continued strength across cellular therapy, medical testing, laboratory services, aesthetics beauty services, and healthcare products. The broad-based growth mix suggests improving operating traction, which is modestly supportive for near-term sentiment.
Revenue grew 44% to $4.9 million, driven by continued strength across cellular therapy, medical testing, laboratory services, aesthetics beauty services, and healthcare products. The broad-based growth mix suggests improving operating traction, which is modestly supportive for near-term sentiment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
